Overview of Bemiparin Sodium

Property	Description
Active ingredient	Bemiparin Sodium
Form	Solution for injection (sterile liquid)
Pharmacological class	Antithrombotic agent, Anticoagulant
Typical use	Prevention of blood clot formation
Origin	Derived from porcine unfractionated heparin

What Type of Medicine is Bemiparin Sodium?

Bemiparin Sodium is an anticoagulant (a blood thinner) and an antithrombotic agent, classified within the Heparin group of medicines. This compound is used to help provide protection against clotting in the blood. A key distinguishing feature is its classification as an ultra-low molecular weight heparin (ultra-LMWH). This designation is based on the drug's exceptionally low average molecular weight (approximately 3,600 Daltons) compared to other LMWHs, which is intended to provide a more targeted and predictable response. The medicine is supplied as a single product and is administered via subcutaneous injection using a sterile solution for injection.

Composition, Origin, and Form

The active ingredient is Bemiparin Sodium, a highly purified substance derived from porcine unfractionated heparin. This means the raw material, extracted from the intestinal mucosa of pigs, undergoes a controlled chemical process of depolymerization and fractionation to yield the consistent Bemiparin molecule. The manufacturing process ensures the product's purity and structure.

General Function: Why is Bemiparin Sodium Used?

Bemiparin Sodium is used for the general function of preventing the formation and growth of dangerous blood clots. It achieves this by selectively boosting a natural protein (antithrombin III) to specifically disable a critical clotting factor known as activated Factor X (Factor Xa). By interrupting this key step, the medicine ensures that blood flow remains smooth and unobstructed, offering its defining general benefit of targeted anticoagulant activity.

What side effects are possible with Bemiparin Sodium?

Possible Side Effects and Safety Information

The safety profile of Bemiparin Sodium, like other low molecular weight heparins, is primarily defined by the risk of bleeding and reactions related to the blood and immune system. All documented adverse reactions are based on official government regulatory classifications.

Frequency Category	Key Adverse Reactions
Very Common (≥1/10)	Haematoma and/or pain at the injection site.
Common (≥1/100 to <1/10)	Minor haemorrhage (e.g., ecchymosis, skin bleeding), mild, transient elevation of liver transaminases (AST, ALT).
Uncommon (≥1/1,000 to <1/100)	Mild, transient thrombocytopenia (Type I), allergic reactions (e.g., urticaria, pruritus).
Rare (≥1/10,000 to <1/1,000)	Major haemorrhage (e.g., cerebral, retroperitoneal, gastrointestinal), severe antibody-mediated thrombocytopenia (Type II HIT), hyperkalaemia, and cutaneous necrosis.

Serious Adverse Reactions

Serious adverse events explicitly documented in regulatory sources include major hemorrhage and severe Type II Heparin-Induced Thrombocytopenia (HIT), which is an antibody-mediated, severe decrease in platelet count. A rare, but serious, risk is the formation of a spinal or epidural haematoma during central neural procedures (like spinal or epidural anesthesia), which may result in prolonged or permanent paralysis.

Safety-Related Restrictions and Precautions

The medicine is strictly contraindicated (must not be used) in patients with a history of confirmed or suspected immunologically mediated HIT, active hemorrhage, an increased risk of bleeding due to impaired haemostasis, severe impairment of liver or pancreatic function, or recent surgery/injury to the central nervous system, eyes, or ears. Caution is also required in patients with severe renal impairment, where regular monitoring is recommended, and in those with pre-existing conditions (such as diabetes, chronic renal failure, or those taking potassium-sparing drugs) due to the risk of hyperkalaemia (elevated potassium levels).

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes the official, regulatory documentation regarding Bemiparin Sodium overdosage and the corresponding required emergency actions.

Overdosage of Bemiparin Sodium, following subcutaneous or other routes of administration, primarily results in hemorrhagic complications (bleeding). As an anticoagulant, the most serious manifestation of excessive effect is the risk of major hemorrhage, which can potentially be fatal.

Overdose Manifestation	Required Action
Hemorrhagic Complications (Bleeding)	Discontinue treatment immediately and seek urgent medical help.
Potential for Fatal Bleeding	Urgent medical evaluation and intervention are required.

Official Management and Antidote

In the event of suspected or confirmed overdosage, the treatment must be discontinued immediately. The official regulatory antidote specified for the neutralization of the anticoagulant effect of Bemiparin is Protamine Sulfate. This antidote is administered via a slow intravenous injection, under medical supervision, to reverse the effects of the medicine.

Patients with severe renal insufficiency (creatinine clearance less than 30 mL/min) are considered a high-risk population. Due to altered drug elimination, Bemiparin may accumulate, increasing the risk of over-anticoagulation and subsequent bleeding complications. Assessment and careful monitoring are required for these patients.

Therapeutic Uses of Bemiparin Sodium

Quick Facts: Bemiparin Sodium

Therapeutic Domain
Supports the management of blood clots (thromboembolism).
Helps prevent the formation of blood clots in the veins (venous thromboembolism) following certain surgical procedures.
Used to prevent blood clotting during specific medical processes, such as haemodialysis.

Bemiparin Sodium is a low molecular weight heparin indicated for the prevention and management of conditions related to blood clot formation. Its primary therapeutic domains involve supporting the circulation to reduce the risk of thromboembolic events.

This medication is used for thromboprophylaxis—the prevention of blood clots in the veins following certain general abdominal or orthopaedic surgical procedures. It is an option for patients who may be at risk for developing venous thromboembolism (VTE).

Additionally, Bemiparin Sodium helps prevent the coagulation of blood within the extracorporeal circuit, which is necessary during medical procedures like haemodialysis. The clinical goal of treatment is to support appropriate blood flow and reduce the potential for complications related to clotting in these specific settings.

Eligibility and Restrictions for Use

Who Can and Cannot Use Bemiparin Sodium: Official Regulatory Information

Populations for Whom Use is Contraindicated

Bemiparin Sodium must not be used in patients with the following conditions, as stated in official regulatory documentation:

A known hypersensitivity to the medicine, other heparins, or any substance of porcine origin.
A history of immunologically mediated Heparin-Induced Thrombocytopenia (HIT).
Active haemorrhage (bleeding) or an increased risk of bleeding due to impaired haemostasis.
Severe impairment of liver or pancreatic function.
Recent injuries to or operations on the central nervous system, eyes, or ears (within the last two months).
Acute or slow bacterial endocarditis or any organic lesion with a high risk of bleeding (e.g., haemorrhagic stroke).

Restricted and Special-Population Use

Paediatric Population: The safety and efficacy have not been established in children due to a lack of data.
Renal Function: Use requires caution in patients with mild or moderate renal impairment and careful monitoring for those with severe impairment.
Pregnancy/Lactation: Use during pregnancy or lactation must be based on a careful risk-benefit assessment by a physician.

What should I know about interactions with other medicines?

The official interaction profile for Bemiparin Sodium is defined by its potential for pharmacodynamic reinforcement and specific constraints related to administration timing and co-administered routes.

Co-administration with medicinal products that interfere with coagulation or platelet function is officially classified as "not advisable" due to the increased risk of bleeding. This restriction applies to various substance classes, including Vitamin K antagonists and other anticoagulants, Acetylsalicylic acid and NSAIDs, platelet inhibitors, systemic glucocorticoids, and Dextran.

A distinct pharmacodynamic interaction involves the risk of hyperkalaemia (elevated potassium levels) when Bemiparin is combined with potassium-sparing drugs. This risk is officially noted as being heightened in populations with conditions such as chronic renal failure or diabetes mellitus.

An interaction resulting in a decrease in Bemiparin's efficacy cannot be ruled out when co-administered with Intravenous Nitroglycerine. Furthermore, a mandatory minimum of four hours must elapse between the removal of an epidural or spinal catheter and the subsequent dose. Due to the risk of hematoma, the intramuscular injection of other agents should be avoided during treatment.

Mechanism of Action

Selective Anti-Factor Xa Potentiation

The mechanism of action centers on a highly selective interaction with the natural anticoagulant protein, Antithrombin III ( AT-III). Bemiparin acts as a catalytic template, binding to AT-III and causing a structural change that dramatically accelerates its ability to neutralize Activated Factor X ( FXa), a critical enzyme in the blood clotting cascade. The AT-III-mediated neutralization of FXa is the molecular step that translates into the resulting physiological consequence of suppressed fibrin polymerization.

Suppression of the Thrombin Burst

By selectively inhibiting FXa, the drug effectively prevents the full activation of the common coagulation pathway and the subsequent conversion of prothrombin to large amounts of Thrombin ( Factor IIa). Since Thrombin is the enzyme that forms the final stable fibrin mesh, suppressing this Thrombin burst is the ultimate physiological consequence, resulting in the lack of stable fibrin formation and subsequent suppression of clot propagation. The ultra-low molecular weight of the drug results in this inhibitory action being highly specific to FXa, with minimal direct neutralization of Thrombin itself.

Augmentation of Endogenous Anticoagulation

Beyond its direct AT-III mediation, the drug also influences the body's native anti-clotting mechanisms by promoting the release and enhancing the activity of Tissue Factor Pathway Inhibitor ( TFPI) from the vascular endothelium. This complementary action contributes to the overall modulation of the coagulation system and the sustained suppression of coagulation factor activation.

Dosage and Administration Information

Administration Method

Bemiparin sodium is typically administered via subcutaneous injection. This involves using a small needle to deliver the medication into the layer of fat directly under the skin. Common injection sites include the abdominal area, avoiding the immediate vicinity of the navel, as well as the upper thighs or the outer aspect of the upper arms.

To ensure proper administration, it is standard practice to rotate injection sites with each dose to minimize the risk of local irritation or bruising. The medication is usually provided in pre-filled syringes designed for single use.

Preparation for Injection

Before administration, the injection site should be clean. The person administering the medication should wash their hands thoroughly. When using a pre-filled syringe, the protective cap is removed just prior to use. It is important not to expel the small air bubble in the syringe before the injection, as this bubble helps ensure the full dose is delivered and reduces the likelihood of bruising at the site.

The Injection Process

The injection is performed by gently pinching a fold of skin between the thumb and forefinger and inserting the needle perpendicularly (at a 90-degree angle) into the skin fold. The plunger is then depressed steadily until the syringe is empty. Once the needle is withdrawn, the skin fold is released.

It is recommended not to rub or massage the site after the injection, as this can increase the risk of localized bleeding or hematoma formation. Used syringes should be disposed of immediately in a designated sharps container to ensure safety.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bemiparin Sodium

Evidence for Preventing Blood Clots After Surgery

The clinical research for Bemiparin Sodium has primarily focused on its use for thromboprophylaxis—the strategy studied for the management of blood clot formation known as Venous Thromboembolism (VTE). This was studied for adults undergoing high-risk procedures such as total hip or knee replacement and major abdominal or pelvic surgery.

The research included several Randomized Controlled Trials (RCTs), which compared Bemiparin Sodium to other established blood thinners. These studies monitored specific outcomes, including the documented incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE). Findings describe patterns observed in these studies where the medicine was evaluated for VTE risk in surgical settings.

The follow-up durations for many of these trials were short-term, generally lasting 7 to 10 days post-operation. However, some studies monitored outcomes over intermediate time intervals, following certain high-risk populations for up to four or six weeks post-discharge.

Evidence for the Treatment of Established Deep Vein Thrombosis

Research also examined the use of Bemiparin Sodium for the acute and long-term management of an existing Deep Vein Thrombosis (DVT). These studies were generally structured as RCTs, comparing the medicine to older treatments like unfractionated heparin for the initial treatment phase.

The studies explored outcomes related to physical discomfort and changes in thrombus size, which was typically monitored by imaging. For the long-term management of DVT, research examined short-term changes in the incidence of blood clot reoccurring, known as recurrence.

What is Still Uncertain About Bemiparin Sodium Research

Despite the existing research, key evidence gaps and limitations have been observed:

Long-Term Outcomes: There is limited information for long-term outcomes of extended use beyond the established trial follow-up periods.
Comparative Evidence: While studies compared the drug to older standard treatments, comparative evidence is lacking against many of the newer anticoagulant medicines that are currently available.
Subgroup Findings: Results apply only to the populations studied. Data for certain high-risk subgroups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Bemiparin Sodium (FAQ)

Q: How is Bemiparin Sodium different from standard unfractionated heparin?

Bemiparin Sodium is classified in official documents as an ultra-low molecular weight heparin (ultra-LMWH). This designation means it has an exceptionally low average molecular weight compared to standard (unfractionated) heparin. This specific structure is intended by the manufacturer to provide a more targeted and predictable anticoagulant (blood-thinning) response in the body.

Q: Why is Bemiparin Sodium used during kidney dialysis?

Regulatory references state that the medicine is officially indicated for the prevention of clotting in the external circuit, or tubing, used during haemodialysis (kidney dialysis). This practice is intended to help keep the patient’s blood flow unobstructed while it is being filtered by the machine.

Q: Can Bemiparin Sodium be used in non-surgical patients who are temporarily immobile?

Official regulatory listings in some countries indicate that Bemiparin Sodium is used for prophylaxis (prevention) in non-surgical patients who are deemed to be at moderate or high risk of Venous Thromboembolism (VTE). This includes patients who are acutely ill and temporarily immobilized due to conditions like heart failure.

Q: What are the general expectations for how long the anticoagulant effect lasts after injection?

According to pharmacokinetic studies, the medicine is quickly absorbed after being injected and has an elimination half-life (the time it takes for half of the dose to be cleared) of approximately five to six hours. Studies in healthy volunteers have measured detectable anti-clotting activity lasting up to 16 hours following the injection.

Q: What are the signs of serious bleeding or hemorrhage that someone should monitor for?

Official regulatory warnings describe signs of serious bleeding that a patient may wish to be aware of. These signs may include unusual bleeding from the gums or nose, vomiting blood or material that looks like coffee grounds, or changes in the color of urine or stool. Sudden, severe headaches are also noted as potential signs of internal bleeding.

Q: Can Bemiparin Sodium affect long-term bone density or cause osteoporosis with prolonged use?

Official research has indicated that Bemiparin is associated with a specific pattern of use where the risk of osteoporosis is considered to be low relative to unfractionated heparin. However, official product information also notes a general lack of long-term information for extended use of Bemiparin Sodium beyond the follow-up periods of the clinical trials.

Q: Are there known interactions with common blood pressure medications, such as ACE inhibitors?

The official product information specifically warns of a risk of hyperkalaemia (elevated potassium levels) when Bemiparin is combined with potassium-sparing drugs. This class of medicine includes certain types of blood pressure medications. This risk is noted as being particularly heightened in patients with pre-existing conditions like diabetes or chronic renal failure.

Q: Is Bemiparin Sodium considered safe for elderly or older patients?

Regulatory guidance indicates that the dosing recommendations for older patients are generally the same as for other adults provided kidney function is normal. Due to the higher likelihood of diminished kidney function in the elderly, official documents state that dose adjustments are generally determined based on the patient's individual kidney status. The medicine has been studied in non-surgical elderly populations for clot prevention.

Q: Can someone with uncontrolled or difficult-to-manage high blood pressure receive this treatment?

Official warnings for heparins note that extreme caution is required in patients with uncontrolled or severe hypertension (high blood pressure). This is because high blood pressure can increase the patient’s underlying risk of hemorrhage (bleeding) during the course of anticoagulant treatment. Blood pressure monitoring is often noted as a consideration in this context.

Q: What evidence exists regarding the use of Bemiparin Sodium in patients with congestive heart failure?

Clinical research evidence shows the medicine has been studied for the prevention of VTE in acutely ill medical patients. This population included those with diagnoses such as heart failure and other pre-existing heart diseases, with researchers monitoring both the incidence of clotting and any bleeding events.

Q: Is it true that the medicine should not be mixed with other injection solutions?

The pre-filled syringe is designed for single use only and must be discarded after the injection. Official warnings advise avoiding the intramuscular injection of other agents during treatment with Bemiparin, as this carries a heightened risk of localized bleeding or hematoma (bruising) near the injection site.

Q: What does the term 'low molecular weight heparin' (LMWH) mean in simple terms?

LMWH refers to a specific type of heparin that has been chemically processed to make its molecules smaller. This smaller molecular structure is designed to provide a targeted effect on the body's clotting factors. Unlike standard heparin, LMWHs like Bemiparin have a structure that generally requires less frequent clinical monitoring.

Q: Is Bemiparin Sodium prescribed for long-term clot prevention outside of a hospital setting?

Bemiparin Sodium is used in some countries for the secondary prevention of VTE, and research has examined use for up to three months. However, official product information also explicitly states there is limited information available for outcomes of use that extends beyond the time periods evaluated in clinical trials.

Q: What is VTE prophylaxis and how does Bemiparin Sodium relate to it?

VTE prophylaxis stands for the prevention of Venous Thromboembolism. VTE is a condition where dangerous blood clots form, such as Deep Vein Thrombosis (DVT) in the legs or Pulmonary Embolism (PE) in the lungs. The medicine is officially indicated for this preventive treatment, especially in patients who are undergoing surgical procedures and are considered to be at high risk.

Q: Are there any specific long-term complications or safety concerns for people using this drug for weeks or months?

The official research overview notes that there is limited information for long-term outcomes of use that extends beyond the established trial follow-up periods. The medicine is associated with a specific pattern of use where the risk of issues like osteoporosis is considered to be low relative to unfractionated heparin. Official documents note that decisions about long-term monitoring are generally based on the established clinical procedures.

Q: How does Bemiparin Sodium compare to Enoxaparin (a similar LMWH) in clinical studies?

Official regulatory documents indicate that comparative evidence is lacking against many of the newer anticoagulant medicines, which includes other low molecular weight heparins like Enoxaparin. Studies that have been conducted in healthy volunteers have shown that Bemiparin achieved a higher area under the curve for anti-Factor Xa activity than Enoxaparin.

How should Bemiparin Sodium be stored and disposed of?

How to Store and Dispose of Bemiparin Sodium?

Bemiparin sodium must be stored below 30°C and must not be frozen to preserve its quality and effectiveness. The medicine is supplied in a pre-filled syringe and must be kept in its original carton to protect the solution from light. Before use, the solution should be checked to ensure it is clear, colorless or slightly yellowish, and free from visible particles. Because the pre-filled syringe is for single use only, any unused medicine or remaining product must be discarded.

To ensure safety, the medication must be stored out of the sight and reach of children. The final disposal of the pre-filled syringes and any waste material must be done in accordance with local requirements. Used needles and syringes should be placed immediately into a dedicated sharps container.

Bemiparin Sodium